BIO101, 20-hydroxyecdysone for COVID-19

 BIO101, 20-hydroxyecdysone has been reported as potentially beneficial for COVID-19 in the following studies.
COVID-19 involves the interplay of 350+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 10,000+ potential treatments. c19early.org analyzes 210+ treatments. We have not reviewed BIO101, 20-hydroxyecdysone in detail.
Lobo et al., Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial, eClinicalMedicine, doi:10.1016/j.eclinm.2023.102383